Company: LHI
Filing Date: 2025-05-23
Form Type: F-1
Source: 0001213900-25-046955
Chunk: 67

Company: Living Homeopathy International Ltd.
Filing Date: 2025-05-23
Form: F-1
Chunk 67
---
 or issue securities to foreign investors. However, as the Overseas Listing Trial Measures were newly published, there are substantial uncertainties that the CSRC may take a view that is contrary to our understanding of the Overseas Listing Trial Measures because the CSRC may have substantial discretions over the determination of “indirect overseas offering and listing by a domestic company”. If we are required to complete the filing procedures with the CSRC in connection with this offering, we cannot assure you that we will be able to complete such filings in a timely manner, or at all, in the future. Any failure by us to comply with such filing could impact our operations materially and adversely, subject us to order to rectify, warnings and fines, and significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of our securities to significantly decline or be worthless.

As of the date of this prospectus, subject
to final determination by the CAC and relevant competent authorities, Han Kun Law Offices, our PRC counsel, has advised that on the
basis that (i) we currently do not have or intend to set up any subsidiary or VIE structure in mainland China, (ii) our business operations
are conducted in Hong Kong, and (iii) we possess personal information of less than one million individuals in the PRC and we have never
been recognized as a critical information infrastructure operator in the PRC,, we are currently not required to obtain any permission
or approval from the CAC, or other governmental authorities of mainland China to operate our business or to list Living Homeopathy’s
securities on the U.S. exchanges and to issue securities to foreign investors, nor have we been denied of any permissions or approvals
from the authorities of mainland China. Furthermore, Han Kun Law Offices LLP, Living Homeopathy’s Hong Kong counsel, has advised
Living Homeopathy that, as of the date of this prospectus, Living Homeopathy is not required to obtain any permission or approval from
the governmental authorities of Hong Kong to list on the U.S. exchanges and offer securities.

However, if we (i) do not receive or maintain such permission or approval, should the permission or approval be required in the future by the government of mainland China or Hong Kong, (ii) inadvertently conclude that such permission or approval is not required, or (iii) applicable laws, regulations, or interpretations change and we are required to obtain such permission or approval in the future, we may be unable to obtain such permissions or approvals in a